Tory J. Nash

Statistics

Publications

Citations

189

H-Index

Active since

2012

Affiliations

AstraZeneca (United States)(Current)

Tory J. Nash is an author at AstraZeneca (United States) specializing in novel antibacterial drug discovery, antibacterial drug development, and antibacterial pharmacology.

Publications per year

2012–2015

Publications

Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in <i>Pseudomonas aeruginosa</i> strains containing derepressed AmpC

Sushmita D. Lahiri, Grant K. Walkup, James Whiteaker et al. · Journal of Antimicrobial Chemotherapy · 2015 · 127 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Discovery of Inhibitors of 4′-Phosphopantetheine Adenylyltransferase (PPAT) To Validate PPAT as a Target for Antibacterial Therapy

Boudewijn L. M. de Jonge, Grant K. Walkup, Sushmita D. Lahiri et al. · Antimicrobial Agents and Chemotherapy · 2013 · 44 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

An aminoquinazoline inhibitor of the essential bacterial cell wall synthetic enzyme GlmU has a unique non-protein-kinase-like binding mode

Nicholas Larsen, Tory J. Nash, Marshall Morningstar et al. · Biochemical Journal · 2012 · 18 citations

Life Sciences, Medicinal Chemistry, Pharmacology +16

1–3 of 3